Securities code: 002755 securities abbreviation: Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Announcement No.: 2022-002
Beijing Aosaikang Pharmaceutical Co.Ltd(002755)
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions.
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) (hereinafter referred to as “the company”) convened the 17th meeting of the 5th board of directors and the 16th meeting of the 5th board of supervisors on November 19, 2021, deliberated and adopted the proposal on continuing to promote the issue of shares and the payment of cash to purchase assets, It is proposed to continue to promote the purchase of 60% equity of Jiangsu weidekang Medical Technology Co., Ltd. by issuing shares and paying cash. For details, please refer to Beijing Aosaikang Pharmaceutical Co.Ltd(002755) announcement on continuing to promote the issue of shares and paying cash to purchase assets (Announcement No.: 2021-088) issued by the company on November 20, 2021. The company has issued the progress announcement of Beijing Aosaikang Pharmaceutical Co.Ltd(002755) on issuing shares and paying cash to purchase assets (Announcement No.: 2021-095) on December 18, 2021.
As of the disclosure date of this announcement, the company is coordinating relevant parties to actively promote the work related to this transaction and further modify, supplement and improve the transaction scheme and relevant materials according to the audit opinions of the audit committee of mergers and acquisitions of listed companies of CSRC and in combination with the actual situation. After the completion of relevant work, the company will perform necessary decision-making and approval procedures in accordance with relevant laws, regulations and the articles of association, and timely perform the obligation of information disclosure.
The information disclosure media designated by the company are securities times, securities daily and http://www.cn.info.com.cn, All information of the company shall be subject to the announcement published in the above designated media. There is still uncertainty in this transaction. Please pay attention to the follow-up announcement and pay attention to the investment risk.
It is hereby announced.
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) board of directors
January 17, 2022
